Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
- 31 May 2011
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Biological Therapy
- Vol. 11 (10), 1381-1394
- https://doi.org/10.1517/14712598.2011.605352
Abstract
Introduction: In vitro and in vivo experimental data have suggested new immunopathogenic mechanisms in primary Sjögren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. Amongst these new treatment modalities, monoclonal antibodies specific for the B-cell surface molecule CD20 have been shown to be the most promising treatment option to date. Areas covered: A search of the Pubmed, MEDLINE, EMBASE, Cochrane and Ovid databases was performed to review literature on the efficacy and safety profile of anti-CD20 therapy in pSS patients. Expert opinion: A single course of the chimeric humanized anti-CD20 antibody rituximab was effective in reducing disease activity in pSS patients for about six to nine months. Retreatment of responders resulted in a similar effect to initial treatment. When combined with corticosteroids during infusion, rituximab was shown to be a safe drug to administer. Thus, anti-CD20 therapy can be considered an effective treatment option in pSS patients. However, large randomized controlled trials with anti-CD20 therapy, for example rituximab, are warranted in order to: 1) assess long-term effects of such treatment, 2) determine which pSS patients will benefit most from anti-CD20 treatment and 3) assess which retreatment schedule should be followed.Keywords
This publication has 95 references indexed in Scilit:
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- BAFF: a local and systemic target in autoimmune diseasesClinical and Experimental Immunology, 2009
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targetsImmunologic Research, 2009
- The Future of Biologic Agents in the Treatment of Sjögren’s SyndromeClinical Reviews in Allergy & Immunology, 2007
- Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF productionAnnals Of The Rheumatic Diseases, 2007
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2007
- Progression of salivary gland dysfunction in patients with Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndromeThe Journal of Pathology, 2004